Glaxo Smith Kline results, Q2 2026
Net profit, assets, equity and cash flow for Q2 2026, against the same period a year earlier, from the published financial statements.
Net profit43.9 millionEGP · −79.4% vs the same period a year earlier
Shareholders' equity2.18 billionEGP · −1.6% vs the same period a year earlier
In short
- Glaxo Smith Kline's net profit for Q2 2026 was about 43.9 million EGP, down −79.4% from 213 million EGP in Q2 2025.
Key lines against the same period a year earlier
This periodQ2 2025Change
Net profit43.9 million213 million−79.4%
Gross profit448 million289 million+55.2%
Total assets—4.5 billion—
Total liabilities—2.28 billion—
Shareholders' equity2.18 billion2.22 billion−1.6%
Total liabilities and equity5.29 billion4.5 billion+17.5%
Operating cash flow—241 million—
Investing cash flow—115 million—
Financing cash flow—48 million—
Net change in cash—404 million—
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Glaxo Smith Kline's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy